Group 1 - The company Weigao Group (01066) announced a share buyback on February 16, 2026, spending HKD 315,900 to repurchase 62,000 shares [1]

Core Viewpoint - The new strategic direction of Bank of East Asia (00023) is clear, with a reduction in credit costs and an increase in non-interest income assumptions, leading to an upward revision of net profit forecasts for 2026E/2027E by 42.5%/49.0% to HKD 5 billion/HKD 5.7 billion [1] Group 1: Financial Performance - The company's 2025 performance was below expectations, with revenue of HKD 21 billion, a year-on-year increase of 0.2%, and net profit of HKD 3.2 billion, a year-on-year decrease of 20.1% [2] - The company's credit cost for 2025 was 1.04%, with a slight year-on-year increase of 1 basis point, and a second half increase of 19 basis points to 1.14% [4] - The net interest income for 2025 decreased by 7.3% due to a decline in HIBOR and LPR, resulting in a narrowing of the interest margin by 19 basis points to 1.90% [5] Group 2: Strategic Goals - The company aims to improve ROE to 7% by 2028, with a goal to double shareholder returns [3] - The strategy includes improving asset quality by resolving historical issues in commercial real estate (CRE) and reducing credit costs to below 60 basis points [3] - The company plans to achieve a compound annual growth rate (CAGR) of approximately 14% in non-interest income over the next three years, focusing on wealth management for affluent clients and leveraging cross-border business advantages [3] Group 3: Asset Management - The company is actively disposing of non-performing assets related to real estate, with 77% of credit costs allocated to CRE-related exposures [4] - By the end of 2025, the company's exposure to mainland property developers accounted for 2.7% of total loans, a decrease of 2.2% year-on-year, while exposure to Hong Kong property developers accounted for 9.9%, a decrease of 1.6% [4] Group 4: Non-Interest Income - Non-interest income for 2025 increased by 28%, with fee income rising by 15% and contributions from wealth management and corporate fees showing double-digit growth [6] - Other non-interest income grew by 50%, primarily driven by client trading and market-making activities, which are considered stable fee-like revenues [6]

贪玩(09890)发布公告，于2026年2月16日该公司斥资1480.98万港元回购75万股，回购价格为每股19.33- 19.87港元。 ...

Core Viewpoint - Geely Automobile (00175) announced a share buyback plan, intending to repurchase 1.68 million shares for a total cost of HKD 28.2814 million [1] Group 1 - The company plans to execute the buyback on February 16, 2026 [1] - The total amount allocated for the share repurchase is approximately HKD 28.28 million [1] - The number of shares to be repurchased is 1.68 million [1]

爱康医疗(01789)发布公告，于2026年2月16日斥资704.3万港元回购114万股。 ...

Core Viewpoint - The approval of SYH2082 by the FDA marks a significant milestone for the company in the development of innovative long-acting products in the metabolic field, with potential benefits for obesity management and type 2 diabetes [1][2] Group 1: Product Development - The company has developed SYH2082, a long-acting GLP-1/GIP receptor dual agonist injection, which has received FDA approval for clinical trials in the U.S. [1] - SYH2082 is designed for monthly administration, enhancing patient compliance and convenience [1] - The product utilizes a long half-life modification platform and long-acting formulation technology to achieve sustained weight loss during the dosing interval [1] Group 2: Clinical Benefits - The approved clinical indication for SYH2082 is weight management in individuals with obesity or overweight with at least one weight-related comorbidity [2] - SYH2082 also shows potential for improving blood glucose control in adults with type 2 diabetes, providing additional clinical benefits [2] Group 3: Preclinical and Toxicology Findings - In preclinical studies, SYH2082 demonstrated superior efficacy in long-term weight loss and maintenance compared to similar marketed products, supporting a monthly dosing regimen [1] - Toxicology studies indicated good tolerability for SYH2082, with no significant adverse reactions observed [1]

智通财经APP讯，爱康医疗(01789)发布公告，于2026年2月16日斥资704.3万港元回购114万股。 ...

临床前研究显示，该产品未见全身系统毒性或新增毒性靶器官，与市售罗哌卡因注射液相比展现出显著 的长效镇痛优势，具有良好的安全性和有效性。 本次获批的临床适应症为术后镇痛。该产品临床试验的获批，有望填补超长效术后镇痛领域迫切的临床 需求，是集团在中枢神经领域的重要成果。 石药集团(01093)发布公告，集团开发的罗哌卡因长效注射液(SYH9089注射液)(该产品)已获得中华人民 共和国国家药品监督管理局批准，可在中国开展临床试验。 该产品可通过抑制神经细胞钠离子通道，阻断钠离子流入神经纤维细胞膜内，从而对沿神经纤维的衝动 传导产生可逆性的阻滞;亦能降低给药频率，满足临床术后的持续镇痛需求，减少患者对阿片类药物的 依赖，避免持续镇痛装置感染或移位风险，从而显著提高治疗依从性及用药安全性。依托集团的长效药 物递送技术平台，该产品可将单次给药镇痛持续时间延长至一周，有望成为中国首款镇痛持续时间达到 一周的超长效镇痛产品。 ...

微泰医疗-B(02235)公布，2026年2月16日耗资约7.89万港元回购1.08万股股份。 ...

希玛医疗(03309)发布公告，于2026年2月16日斥资22.35万港元回购15万股。 ...